HARP Live-Signale | Maximieren Sie Profite mit Getagraph.com

KAUFEN 108150 min ago

@ $22.46

Ausgestellt: 14 Feb 2024 @ 18:29

Rendite: 2.45%

Vorheriges Signal: Feb 14 - 15:30

Vorheriges Signal: Verkaufen

Rendite: -0.29 %

Live Chart Being Loaded With Signals

Commentary (8 Mär 2024 @ 22:00):

Stats
Tagesvolumen	6.40M
Durchschnittsvolumen	1.13M
Marktkapitalisierung	865.08M
EPS	$0 ( 2024-03-25 )
Nächstes Ertragsdatum	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.04
ATR14	$0.377 (1.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	395 783	Common Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	10 000	8.000% Series A Redeemable Preferred Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	299 430	Common Stock Warrant (Right to Buy)
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	85 750	Common Stock Warrant (Right to Buy)
2024-03-11	Silvernail Lauren P	Sell	5 000	Common Stock

INSIDER POWER
75.66
Last 96 transactions
Buy: 30 137 007 \| Sell: 5 308 481

Volumen Korrelation

Lang: 0.48 (neutral)

Kurz: 0.40 (neutral)

Signal:(82.718) Neutral

Harpoon Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
APOP	0.898
RMRM	0.892
PAIC	0.857
TDAC	0.851
GAINL	0.843
TLGT	0.841
ISNS	0.821
SVAC	0.813
SPRT	0.808

10 Am meisten negativ korreliert
MMAC	-0.899
BOCH	-0.892
NETE	-0.858
AMRB	-0.844
SHSP	-0.811
DSPG	-0.808

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Harpoon Therapeutics Inc Korrelation - Währung/Rohstoff

-0.16
( neutral )

0.64
( weak )

0.52
( weak )

0.07
( neutral )

0.59
( weak )

0.29
( neutral )

Harpoon Therapeutics Inc Finanzdaten

Annual	2022
Umsatz:	$31.92M
Bruttogewinn:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2022
Umsatz:	$31.92M
Bruttogewinn:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2021
Umsatz:	$23.65M
Bruttogewinn:	$23.65M (100.00 %)
EPS:	$-3.62

FY	2020
Umsatz:	$17.44M
Bruttogewinn:	$17.44M (100.00 %)
EPS:	$-1.990

Financial Reports:

No articles found.

Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.